Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Sniper007on Apr 17, 2014 6:55pm
144 Views
Post# 22465994

RE:RE:Irked

RE:RE:IrkedI agree KayakerBC that successful phase I and Phase II studies would do wonders for the stock but when it that going to happen? New licensing deals, however, may be non-disclosure dollar deals much like the Medimmune deal which leaves us in the dark and our sp in the crapper. Medimmune, rightly so, does not want to give anything to the other pharmas in terms of what they may or may not be paying but it could be huge dollars for all we know. BTI has not yet publicly decided what direction they're taking BT2111 but it doesn't look like they'll be going it alone if they do move it forward. Because they haven't given any indication whatsoever, it says to me they may have something already in the hopper related to that. That said, I find it difficult to visualize BTI having a sp anywhere near GEVA in the short term or mid term the way it's going right now and it is this forum alone that "believes" extraordinary share price increases are indeed possible. I'm beginning to doubt it, unfortunately. Maybe I'm just losing my patience with this company right now. Hold our nose, cross our fingers and wait, right? Hopefully Jd's prediction that something significant happens in 2-3 weeks materializes. Happy Easter all. Sniper
Bullboard Posts